Plant ID: NPO17024
Plant Latin Name: Vitis vinifera
Taxonomy Genus: Vitis
Taxonomy Family: Vitaceae
NCBI TaxonomyDB:
29760
Plant-of-the-World-Online:
n.a.
Analgesic; Antiinflammatory; Astringent; Bach; Demulcent; Diuretic; Hepatic; Laxative; Lithontripic; Miscellany; Skin; Stomachic
Turkey; Israel; Italy; Lebanon; India; United States; Jordan; Thailand; China; Spain
TSHR; NPSR1; | |
TAAR1; | |
CDC25B; | |
ALPL; RECQL; TDP1; PIK3CA; PIK3CB; GLO1; PGD; ALOX12; GFER; HSD17B10; NQO2; NOX4; APEX1; POLB; | |
ACHE; | |
BCL2; | |
TOP2A; | |
MET; FLT3; CDK1; MAPK1; PIM1; AXL; KDR; IGF1R; AURKB; | |
CA2; CA12; CA9; CA14; CA4; CA7; | |
ESR1; | |
NR1H4; | |
KDM4E; | |
PTGS1; PTGS2; | |
NFKB1; | |
FUT7; | |
SLCO1B1; | |
LMNA; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 | CHEMBL5857 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.084E-12 | 1.180E-08 | CA12, CA14, CA2, CA4, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.445E-09 | 1.966E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.861E-08 | 1.266E-05 | ALPL, APEX1, CYP1A1, CYP1B1, ESR1, FLT3, MAPK1, NFKB1, NOX4, PTGS2 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.177E-08 | 1.394E-05 | ALOX12, AURKB, AXL, BCL2, CDK1, GLO1, IGF1R, KDR, LMNA, NFKB1, NR1H4, PIK3CA, PIM1, PTGS2 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.358E-08 | 1.976E-05 | CA12, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.749E-08 | 2.148E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS1, PTGS2 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.069E-07 | 5.401E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.392E-07 | 1.273E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 1.516E-06 | 4.522E-04 | AXL, NFKB1, NOX4, NR1H4, PIK3CA, PIK3CB, POLB, PTGS1, PTGS2 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.934E-06 | 5.398E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.973E-06 | 5.437E-04 | ALOX12, BCL2, CDC25B, CDK1, ESR1, FLT3, IGF1R, KDR, MAPK1, PIM1, PTGS2, TSHR |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 2.654E-06 | 6.962E-04 | IGF1R, PIK3CA, PIK3CB |
BP | GO:0009987; cellular process | GO:0055082; cellular chemical homeostasis | 5.581E-06 | 1.185E-03 | BCL2, CA2, CA7, ESR1, MAPK1, NOX4, NPSR1, NR1H4, PIK3CA, PIK3CB |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 6.567E-06 | 1.349E-03 | APEX1, POLB |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 6.567E-06 | 1.349E-03 | PTGS1, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 6.817E-06 | 1.387E-03 | ALPL, AXL, CYP1A1, CYP1A2, NFKB1, NR1H4, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 7.217E-06 | 1.442E-03 | APEX1, IGF1R, MAPK1, NFKB1, NOX4, NR1H4, PTGS2, TSHR |
CC | GO:0016020; membrane | GO:0005886; plasma membrane | 8.760E-06 | 1.673E-03 | ACHE, ALOX12, ALPL, AXL, CA12, CA14, CA2, CA4, CA9, ESR1, FLT3, GLO1, HSD17B10, IGF1R, KDR, L3MBTL1, MAPK1, MET, NPSR1, PIK3CA, PIK3CB, PIM1, SLCO1B1, TAAR1, TDP1, TSHR |
BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 1.631E-05 | 2.864E-03 | ALOX12, BCL2, IGF1R, KDR, MAPK1, MET, NOX4, PTGS2 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.859E-05 | 3.163E-03 | APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.967E-05 | 3.244E-03 | CA2, CA7 |
BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 1.967E-05 | 3.244E-03 | BCL2, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.967E-05 | 3.244E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.100E-05 | 3.355E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.787E-05 | 4.304E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 3.590E-05 | 5.415E-03 | AXL, KDR, PIK3CA, PIK3CB |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.671E-05 | 5.474E-03 | CA12, CA2, CA4, CA7, CA9, ESR1, GLO1, L3MBTL1, NQO2, NR1H4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.927E-05 | 5.663E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.927E-05 | 5.663E-03 | CYP1A2, CYP3A4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 4.499E-05 | 6.143E-03 | AXL, MET, NOX4, PIK3CA, PIK3CB |
MF | GO:0005488; binding | GO:0000166; nucleotide binding | 4.836E-05 | 6.458E-03 | AURKB, AXL, CDK1, FLT3, GFER, IGF1R, KDR, MAPK1, MET, NOX4, NQO2, PIK3CA, PIK3CB, PIM1, RECQL, TOP2A |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.744E-05 | 7.534E-03 | ALOX12, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 6.534E-05 | 8.419E-03 | CYP1A1, CYP3A4 |
BP | GO:0009987; cellular process | GO:1901989; positive regulation of cell cycle phase transition | 6.580E-05 | 8.429E-03 | APEX1, CDC25B, CDK1, CYP1A1 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 7.060E-05 | 8.886E-03 | AURKB, AXL, CDK1, FLT3, IGF1R, KDR, MAPK1, MET, PIK3CA, PIK3CB, PIM1, RECQL, TOP2A |
BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 7.984E-05 | 9.878E-03 | ACHE, ALOX12, CYP1A1, CYP3A4, PIK3CA, PIK3CB, PTGS1, PTGS2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.169E-12 | 3.405E-10 | CA12, CA2, CA4, CA7, CA9, CA14 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 5.896E-09 | 4.628E-07 | PIK3CA, FLT3, PIM1, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.572E-08 | 2.393E-06 | PIK3CA, PIM1, BCL2, CYP1B1, MAPK1, PTGS2, MET, NFKB1, CDC25B |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 8.888E-08 | 3.489E-06 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.895E-07 | 4.777E-06 | PIK3CA, PIM1, BCL2, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.583E-07 | 4.777E-06 | PIK3CA, CDK1, MAPK1, PIK3CB, CDC25B, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.333E-07 | 8.341E-06 | PIK3CA, FLT3, BCL2, MAPK1, PIK3CB, PTGS2, MET, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.130E-07 | 4.777E-06 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.759E-07 | 5.415E-06 | PIK3CA, PIK3CB, PTGS2, TSHR, PTGS1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 4.257E-07 | 7.427E-06 | PIK3CA, KDR, MAPK1, PIK3CB, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.906E-07 | 8.341E-06 | PIK3CA, KDR, MAPK1, PIK3CB, ESR1, MET, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 6.681E-07 | 8.341E-06 | PIK3CA, KDR, BCL2, MAPK1, PIK3CB, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 6.834E-07 | 8.341E-06 | PIK3CA, FLT3, MAPK1, PIK3CB, MET |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.459E-06 | 1.348E-05 | PIK3CA, KDR, MAPK1, PIK3CB, MET, NFKB1, IGF1R |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.303E-06 | 1.279E-05 | PIK3CA, LMNA, BCL2, MAPK1, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.893E-06 | 1.564E-05 | PIK3CA, KDR, BCL2, MAPK1, PIK3CB, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 9.144E-07 | 1.025E-05 | PIK3CA, MAPK1, PIK3CB, MET, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 9.808E-07 | 1.027E-05 | PIK3CA, MAPK1, PIK3CB, ESR1, NFKB1 |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 8.351E-06 | 5.700E-05 | ACHE, PIK3CA, BCL2, MAPK1, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 2.378E-06 | 1.867E-05 | PIK3CA, BCL2, PIK3CB, PTGS2, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 7.990E-06 | 5.700E-05 | PIK3CA, MAPK1, PIK3CB, PTGS2, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.877E-06 | 1.564E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.176E-05 | 7.100E-05 | POLB, PIK3CA, CDK1, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.125E-05 | 7.100E-05 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.386E-05 | 7.502E-05 | PIK3CA, KDR, MAPK1, PIK3CB, MET, IGF1R |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.221E-05 | 7.100E-05 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 7.312E-06 | 5.467E-05 | CYP1A1, CYP1B1, PTGS2, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.221E-05 | 7.100E-05 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.148E-05 | 1.369E-04 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.091E-05 | 1.057E-04 | PIK3CA, MAPK1, PIK3CB, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.733E-05 | 9.067E-05 | PIK3CA, BCL2, MAPK1, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.222E-05 | 1.057E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 2.222E-05 | 1.057E-04 | PIK3CA, MAPK1, PIK3CB, MET |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 3.313E-05 | 1.369E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 3.313E-05 | 1.369E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.327E-05 | 7.443E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 8.930E-05 | 3.595E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.092E-04 | 4.287E-04 | PIK3CA, MAPK1, PIK3CB, ESR1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.366E-04 | 4.766E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1, TSHR |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.465E-04 | 4.894E-04 | PIK3CA, BCL2, CDK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.968E-05 | 1.369E-04 | SLCO1B1, CA2, NR1H4, CYP3A4 |
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.322E-04 | 4.766E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.322E-04 | 4.766E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.313E-05 | 1.369E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.423E-04 | 4.857E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.760E-04 | 5.756E-04 | MAPK1, ALOX12, PTGS2, PTGS1 |
09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 2.443E-04 | 7.522E-04 | PIK3CA, MAPK1, PIK3CB, PTGS1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.150E-04 | 6.890E-04 | PIK3CA, MAPK1, PIK3CB, ESR1 |
09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 3.300E-04 | 9.695E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.396E-04 | 9.695E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.396E-04 | 9.695E-04 | PIK3CA, MAPK1, PIK3CB, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.353E-04 | 1.199E-03 | PIK3CA, MAPK1, PIK3CB, IGF1R |
09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 5.090E-04 | 1.332E-03 | PIK3CA, BCL2, MAPK1, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 6.508E-04 | 1.587E-03 | PIK3CA, PIM1, BCL2, PIK3CB |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 8.477E-04 | 1.957E-03 | FUT7, CYP1A2, CYP1A1, ALPL, ALOX12, PTGS2, PGD, CYP3A4, HSD17B10, PTGS1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 6.508E-04 | 1.587E-03 | PIK3CA, MAPK1, PIK3CB, PTGS2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 9.530E-04 | 2.168E-03 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.058E-03 | 2.340E-03 | FLT3, MET, NFKB1, IGF1R |
09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 1.218E-03 | 2.657E-03 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 3.912E-03 | 7.226E-03 | POLB, PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.892E-03 | 3.858E-03 | PIK3CA, ALOX12, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 2.981E-04 | 8.999E-04 | PIK3CA, MAPK1, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 4.551E-04 | 1.232E-03 | PIK3CA, MAPK1, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 1.629E-03 | 3.364E-03 | PIK3CA, MAPK1, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.562E-03 | 4.966E-03 | PIK3CA, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.344E-03 | 2.891E-03 | PIK3CA, MAPK1, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 6.572E-04 | 1.587E-03 | PIK3CA, MAPK1, PIK3CB |
09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 3.604E-03 | 6.817E-03 | CDK1, MAPK1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.062E-03 | 4.099E-03 | PIK3CA, MAPK1, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 4.774E-03 | 8.614E-03 | PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 4.676E-03 | 8.537E-03 | PIK3CA, MAPK1, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 5.595E-03 | 9.870E-03 | PIK3CA, MAPK1, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 2.005E-03 | 4.035E-03 | PIK3CA, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 3.687E-03 | 6.891E-03 | PIK3CA, PIK3CB, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 5.072E-03 | 9.049E-03 | PIK3CA, MAPK1, PIK3CB |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 5.502E-04 | 1.416E-03 | PIK3CA, PIK3CB, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 3.712E-04 | 1.041E-03 | PIK3CA, MAPK1, PIK3CB |
09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 1.261E-04 | 4.766E-04 | PIK3CA, MAPK1, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 8.085E-04 | 1.923E-03 | MAPK1, PTGS2, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 1.629E-03 | 3.364E-03 | BCL2, PTGS2, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 8.411E-04 | 1.957E-03 | MAPK1, MET, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 9.802E-04 | 2.199E-03 | PIK3CA, PIK3CB, MET |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 5.758E-04 | 1.458E-03 | CYP1A2, CYP1A1, CYP3A4 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 2.349E-04 | 7.376E-04 | PIK3CA, MAPK1, PIK3CB |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.012E-04 | 1.332E-03 | ALOX12, PTGS2, PTGS1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.361E-04 | 4.766E-04 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 5.662E-03 | 9.877E-03 | PIK3CA, PIK3CB |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 3.078E-03 | 5.893E-03 | POLB, APEX1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.382E-03 | 4.674E-03 | CYP1A2, CYP3A4 |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.499E-03 | 3.179E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PTGS2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; PIK3CA; KDR; FLT3; MAPK1; PIK3CB; CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; PIK3CA; KDR; NFKB1; FLT3; ACHE; MAPK1; PTGS2; PIK3CB; NQO2; CDC25B; CA9; BCL2; |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
NA: NA | Edema | NA | CA2; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; NQO2; CA9; BCL2; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; PTGS1; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; BCL2; |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; BCL2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
NA: NA | Joint and muscular pain | NA | PTGS2; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; BCL2; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
NA: NA | Menopausal disorder | NA | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS1; PTGS2; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; BCL2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; PTGS1; PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
NA: NA | Miosis during ocular surgery | NA | PTGS1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; PTGS2; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; BCL2; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |